Drug Profile
Idrevloride - Parion Sciences
Alternative Names: GS-5737; P-1037; VRT1499138; VX-371Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Parion Sciences
- Developer Parion Sciences; Vertex Pharmaceuticals
- Class Amides; Amines; Antibronchitics; Chlorine compounds; Pyrazines; Small molecules
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis; Primary ciliary dyskinesia
Most Recent Events
- 08 Sep 2023 Parion Sciences plans a phase III trial for Primary ciliary dyskinesia (Inhalation)
- 30 Nov 2022 Idrevloride is still in phase II trial for Primary ciliary dyskinesia (Parion Sciences pipeline, November 2022)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cystic-fibrosis(Adjunctive treatment) in USA (Inhalation)